NCT03295877View on ClinicalTrials.gov

Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 21, 2017

Primary Completion Date

November 20, 2018

Study Completion Date

November 20, 2018

Conditions
Geographic Atrophy
Interventions
DRUG

RO7171009

Patients will receive RO7171009 via ITV injection.

Trial Locations (13)

28803

Western Carolina Retinal Associate PA, Asheville

30060

Georgia Retina PC, Marietta

32503

Retina Specialty Institute, Pensacola

32901

Florida Eye Associates, Melbourne

37203

Tennessee Retina PC., Nashville

63128

The Retina Institute, St Louis

89502

Sierra Eye Associates, Reno

93103

California Retina Consultants, Santa Barbara

93309

California Retina Consultants, Bakersfield

93454

California Retina Consultants - Santa Maria, Santa Maria

94040

Northern California Retina Vitreous Associates, Mountain View

95825

Retinal Consultants Med Group, Sacramento

80909-1183

Retina Consultants of Southern Colorado PC; Clinical Research Department, Colorado Springs

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT03295877 - Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) | Biotech Hunter | Biotech Hunter